title: Cefpodoxime proxetil in the treatment of skin and soft tissue infections.
abstract: Patients with skin and soft tissue infections were enrolled in a study comparing 2 dosage regimens of orally administered cefpodoxime proxetil; 204 patients with mild to moderate infections received cefpodoxime proxetil 200mg twice daily and 47 patients with severe infections received 400mg twice daily. Both dosage regimens were given for 7 to 14 days. 132 of 142 (93.0%) evaluable patients in the 200mg group and 22 of 29 (75.9%) in the 400mg group were clinically cured post-therapy, the remainder in both groups being classified as improved. The pathogen eradication rate at the end of therapy in the 200mg group was 161 of 165 (97.6%), and 38 of 38 (100%) in the 400mg group. Adverse reactions (drug-related) were reported by 20 (8.0%) patients overall, and there was no apparent relationship between the dosage group and the incidence of adverse reactions. The most commonly reported reactions involved the gastrointestinal tract (diarrhoea) or female genital tract (vaginitis). Cefpodoxime proxetil appears to be a useful and safe agent in the therapy of skin and soft tissue infections.
authors.affiliation: Parke Davis, Ann Arbor, Michigan.
authors.forename: K J
authors.initials: KJ
authors.lastname: Tack
authors.forename: N E
authors.initials: NE
authors.lastname: Wilks
authors.forename: G
authors.initials: G
authors.lastname: Semerdjian
authors.forename: C H
authors.initials: CH
authors.lastname: Frazier
authors.forename: K
authors.initials: K
authors.lastname: Shirin
authors.forename: A
authors.initials: A
authors.lastname: Puopolo
authors.forename: S G
authors.initials: SG
authors.lastname: Crossland
authors.forename: B S
authors.initials: BS
authors.lastname: Goffe
authors.forename: L
authors.initials: L
authors.lastname: Millikan
mesh_terms: D000038:Abscess / Q000188:drug therapy / Q000382:microbiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015296:Ceftizoxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002481:Cellulitis / Q000188:drug therapy* / Q000382:microbiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011355:Prodrugs / Q000009:adverse effects / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy* / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology; D013290:Streptococcal Infections / Q000188:drug therapy; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000382:microbiology; D000097627:Cefpodoxime Proxetil
chemical_list: D015296:Ceftizoxime; D011355:Prodrugs; D000097627:Cefpodoxime Proxetil